News | Nuclear Imaging | November 07, 2018

MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine

New market report notes that approximately $10 billion in M&A transactions have occurred over the past four years, with signs indicating continuing future growth

MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine

November 7, 2018 — With the recent announcement by Novartis to acquire Endocyte , interest from the conventional pharmaceutical industry towards radiopharmaceuticals and in particular radiotherapeutics and radiotheranostics is clearly growing, as foreseen a few years ago by MEDraysintell.

Numerous major acquisitions have involved the conventional pharmaceutical industry over the past four years:

  • In 2014, Bayer acquired Algeta ASA and its major drug for end-stage prostate cancer treatment 223Ra-Xofigo for about NOK 17.6 billion ($2.9 billion), while Novartis took over Advanced Accelerator Applications (AAA) and its Neuro Endocrine Tumor treatment 177Lu-Lutathera in January 2018 for a total value of $3.9 billion;
  • Additionally Novartis announced in October 2018 the acquisition of the company Endocyte developing the prostate cancer drug 177Lu-PSMA-617 for a total value of $2.1 billion. This transaction is expected to be completed in the first half of 2019.
  • Ipsen Pharma acquired in May 2015 the German company OctreoPharm Sciences GmbH, for a total of EUR 50 million (about $55 million) and one year later a large part of the radiopharmaceutical pipeline of the German company 3B Pharmaceuticals GmbH; and
  • Sun Pharmaceutical Industries acquired Pharmalucence in July 2014 for an undisclosed amount.

MEDraysintell noted that other mergers within the radiopharmaceutical industry showed consolidation of this industry:

  • IBA Molecular acquired the Nuclear Medicine business of Mallinckrodt in January 2017 for a total of about $690 million;
  • Jubilant Draximage acquired the Triad Isotopes radiopharmacy network in May 2017; and
  • Sofie Biosciences took over Zevacor Pharma in May 2017.

The company said there are great chances that additional mergers and acquisitions (M&A) will take place within the next 12 months. At the same time, the conventional pharmaceutical industry is now looking for new opportunities in early-stage research programs in this area. MEDraysintell anticipates that the global market will reach $5.9 billion in 2019, and it is now expected that radiotherapeutics will represent more than 60 percent of the $26 billion nuclear medicine market by 2030.

Most of the development of new radiopharmaceuticals is performed by new medium-sized radiopharmaceuticals companies and conventional pharmaceutical corporations. MEDraysintell said these companies are extensively covered in the new Nuclear Medicine Report & Directory, Edition 2018.

For more information: www.medraysintell.com

Related Content

Prof. Dr. Samer Ezziddin from Saarland University/Saarland University Hospital.

Prof. Dr. Samer Ezziddin from Saarland University/Saarland University Hospital. Photo courtesy of Thorsten Mohr/Saarland University

News | Prostate Cancer | November 28, 2019
November 28, 2019 — Reports of new cancer treatments
 Prostate cancer MRI
News | Clinical Trials | November 15, 2019
November 15, 2019 — Theragnostics, which is developing innovative radiopharm
Philips Medical System is recalling its older Forte Gamma Camera SPECT imaging systems due to the possibility of the detectors falling off of the unit onto the patient. The two gamma cameras can bee seen in this photo on either side of the patient bed. These can be rotated above the patient.

Philips Medical System is recalling its older Forte Gamma Camera SPECT imaging systems due to the possibility of the detectors falling off of the unit onto the patient. The two gamma cameras can be seen in this photo on either side of the patient bed. These can be rotated above the patient.

Feature | Nuclear Imaging | November 05, 2019 | Dave Fornell, Editor
November 5, 2019 — Philips Medical System is recalling the Forte Gamma Camera System due to the potential for the 660
 Phoenix’s fusion neutron generation technology.
News | Radiopharmaceuticals and Tracers | October 28, 2019
October 28, 2019 — Phoenix LLC and Shine Medical Technologies LLC, nuclear technology companies focused on near-term
GE Healthcare and Theragnostics Partnering on PSMA PET/CT Imaging Agent
News | Prostate Cancer | October 16, 2019
GE Healthcare and Theragnostics have entered into a global commercial partnership for a new prostate-specific membrane...
ASNC Announces Multisocietal Cardiac Amyloidosis Imaging Consensus
News | Cardiac Imaging | September 09, 2019
September 9, 2019 — The American Society of Nuclear Cardiology (ASNC) published a new expert consensus document along
A 3-D printed tungsten pre-clinical X-ray system collimator. 3D printed, additive manufacturing for medical imaging.

A 3-D printed tungsten pre-clinical X-ray system collimator. The tungsten alloy powder is printed into the form desired and is laser fused so it can be machined and finished. Previously, making collimators from Tungsten was labor intensive because it required working with sheets of the metal to create the collimator matrix. 

Feature | Medical 3-D Printing | September 04, 2019 | By Steve Jeffery
In ...